Pharmacological TreatmentsDiabetes Complications

Effectiveness of GLP-1 Receptor Agonists in T2DM and Obesity


BMJ Open


Effectiveness of GLP-1 Receptor Agonists in T2DM and Obesity

Summary

This retrospective cohort study evaluates the impact of GLP-1 receptor agonists on BMI and blood glucose levels in patients with T2DM and obesity. Using difference-in-difference analysis, it compares GLP-1RA with other second-line antidiabetic treatments over a 24-month period. Findings indicate significant BMI reduction and improved glycaemic control in the GLP-1RA group, suggesting its preference for obese T2DM patients not responsive to metformin monotherapy.

Study Design

Interventions

exenatideliraglutidesemaglutide

Study Type

Cohort

Outcomes

BMI reductionFPG controlBMI reductionHbA1c improvementBMI reductionFPG and HbA1c control

Duration and Size

Long-Term (1–5 y)
Medium size (100–500)

Study Population

Age Range

Middle Aged (40-64)Older Adults (65+)

Sex

MaleFemale

Geography

Asia-Pacific (APAC)

Other Criteria

with T2 Diabeteswith Obesity

Methodology

Data were collected retrospectively from patients receiving GLP-1RA or other second-line treatments. Analysis used linear mixed-effect regression with inverse probability weighting to adjust for confounders.

Interventions

Interventions included GLP-1RAs such as exenatide, liraglutide, and semaglutide administered over 24 months.

Key Findings

GLP-1RA treatments led to greater reductions in BMI and blood glucose compared with other therapies, supporting their use for T2DM with obesity.

Comparison with other Studies

The findings align with previous RCTs and observational studies indicating sustained BMI and glucose improvements with GLP-1RA.

Journal Reference

Siriyotha S, Anothaisintawee T, Looareesuwan P, et al. Effectiveness of GLP-1 receptor agonists for reduction of BMI and blood glucose in T2DM. BMJ Open. 2024;14:e086424. doi:10.1136/bmjopen-2024-086424.

Related and Discussions

experts

Exploring GLP-1 Receptor Agonists with Dr. Bart van der Schueren

Dr. Bart van der Schueren
experts

GLP-1 Agonists: Wonder Drugs of the 21st Century?

Yale School of Medicine Experts
experts

Navigating GLP-1 Agonists: A Comprehensive Journey Through Past, Present, and Future Perspectives

Department of Medicine Grand Rounds
experts

The Future of GLP-1 Receptor Agonists: A Precision Medicine Approach

Quest Diagnostics Webinar
experts

Expert Discusses GLP-1 Receptor Agonists for Treatment of Diabetes

Pharmacy Times Interview
online

GLP-1 Receptor Agonists: An Overview

WebMD
online

GLP-1 Agonists for Type 2 Diabetes

Healthline
online

GLP-1 Receptor Agonists in Type 2 Diabetes Treatment

American Diabetes Association
online

GLP-1 Receptor Agonists: Benefits and Side Effects

Mayo Clinic
online

Understanding GLP-1 Receptor Agonists

National Institutes of Health
reddit

Popular diabetes and obesity drugs also protect kidneys, study ...

u/SaltZookeepergame691
reddit

Why Are GLP-1 Agonists Prescribed?

u/AutoModerator
reddit

GLP-1s like Ozempic are among the most important drug ...

u/AutoModerator
reddit

Any GLP-1 Agonist users here? (Wegovy, Ozempic, etc)

u/AutoModerator
reddit

About 1 in 8 US adults has tried or uses GLP-1 medication ...

u/AutoModerator
studies

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management

Endocrine Practice
studies

Comparative Effectiveness of GLP-1 Receptor Agonists on Glycaemic Control and Weight Loss in Type 2 Diabetes

The BMJ
studies

Efficacy and Safety of GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Overweight or Obese Patients

BMJ Open
studies

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Overweight and Obese Patients

PLOS ONE
studies

Systematic Review and Meta-Analysis for Prevention of Major Adverse Cardiac Events with GLP-1 Receptor Agonists

Scientific Reports
𝕏

The era of GLP-1 receptor agonists in diabetes and obesity management

Rexford S. Ahima, MD, PhD
𝕏

New study compares semaglutide and tirzepatide in overweight/obesity

Juan Turnes
𝕏

Potential impact of GLP-1 receptor agonists on global mortality linked to obesity and type 2 diabetes

Dr. Peter A Singer, OC
𝕏

Preliminary studies suggest GLP-1 receptor agonists may have psychiatric benefits

Sociedad Española de Psiquiatría Legal
𝕏

Happy New Year from @TheLancetEndo featuring GLP-1 receptor agonists

Daniel J Drucker
youtube

Role of GLP-1 Receptor Agonists for Weight Loss

Harvard Medical School
youtube

Exploring GLP-1 receptor agonists with Dr Bart van der Schueren

Novo Nordisk
youtube

Expert Insights on GLP-1: Transforming Obesity & Diabetes Management

Medscape
youtube

GLP-1 Receptor Agonists: Which Drug for Which Patient?

Mayo Clinic
youtube

How GLP-1 Receptor Agonists Evolved from Diabetes to Obesity Treatment

Science Magazine

Stay informed. Stay ahead.

Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.